Showing 4711-4720 of 7240 results for "".
- Healthcare Spending Growth Expected to Remain Lowhttps://practicaldermatology.com/news/20120603-healthcare_spending_growth_expected_to_remain_low/2459793/
- New Technology Helps Identify Two Rare Skin Cell Subtypeshttps://practicaldermatology.com/news/20120515-new_technology_helps_identify_two_rare_skin_cell_subtypes/2459799/
- "Skin Rules" Hits Market March 13https://practicaldermatology.com/news/20120307-skin_rules_hits_market_march_13/2459854/Skin Rules (St. Martin's Press), a new book by dermatologist Debra Jaliman, MD, goes on sale March 13. According to a release, the book "lays out clear, easy-to-understand information on the latest technologies, such as Cool Sculpting (body co
- Health Canada Approves BMS' Yervoy forhttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for/2459870/
- Icotrokinra Shows Sustained Skin Clearance Through 52 Weeks in Psoriasishttps://practicaldermatology.com/news/icotrokinra-shows-sustained-skin-clearance-through-52-weeks-in-psoriasis/2486494/New 52-week data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the sustained efficacy and safety of icotro
- Tapinarof Shows Rapid Itch and Skin Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/tapinarof-shows-rapid-itch-and-skin-improvement-in-atopic-dermatitis/2486493/New pooled Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the rapid onset and consistent efficacy of tapinarof cream 1% (VTAMA; Organon) in patients with moderate-to-severe atopic dermatitis (AD), including children as young as 2 years. Th
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://practicaldermatology.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.
- TRuE-AD4: Ruxolitinib Cream Improves QoL and Sleep in Moderate ADhttps://practicaldermatology.com/news/true-ad4-ruxolitinib-cream-improves-qol-and-sleep-in-moderate-ad/2486434/Ruxolitinib cream 1.5% demonstrated consistent improvements in patient-reported outcomes among adults with moderate atopic dermatitis (AD) who previously had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcine
- Zumilokibart Shows Rapid Symptom Relief in Atopic Dermatitishttps://practicaldermatology.com/news/zumilokibart-shows-rapid-symptom-relief-in-atopic-dermatitis/2486425/Zumilokibart (APG777), a half-life–extended anti–IL-13 monoclonal antibody, demonstrated rapid and sustained improvements in symptoms and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to Phase 2 APEX Part A results presented by Emma Guttman-Yassky, MD, PhD,